Table 6.

Univariate regression analysis of biomarkers serum levels against 12-month clinical progression in a cohort of 34 patients with IPF

Biomarker	Hazard Ratio (C.I.)	p value
Periostin (> 338 ng/ml or increase > 338 from baseline)	1.00 (0.99–1.00) 4.25 (1.53–15.00)	0.0693 < 0.0001
Osteopontin	1.00 (0.99–1.00)	n.s.
KL-6	0.98 (0.76–1.25)	n.s.
MMP-9	1.00 (1.00–1.00)	n.s.
Surfactant protein A	1.00 (1.00–1.00)	n.s.
CCL-18	1.00 (0.99–1.02)	n.s.

n.s. not significant, KL-6 Krebs von den Lungen-6, MMP-9 Matrix Metalloproteinase 9, CCL-18 C-C Motif Chemokine Ligand 18